Gilead Sciences (NASDAQ:GILD) Price Target Raised to $140.00

Gilead Sciences (NASDAQ:GILD) had its price objective increased by Citigroup from $135.00 to $140.00 in a research note published on Wednesday morning,Benzinga reports. Citigroup currently has a buy rating on the biopharmaceutical company’s stock.

Other analysts have also issued reports about the company. Needham & Company LLC lifted their price target on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Wall Street Zen upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 3rd. UBS Group initiated coverage on shares of Gilead Sciences in a report on Wednesday. They issued a “buy” rating and a $145.00 price target on the stock. TD Cowen raised their price objective on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Finally, HSBC lifted their price objective on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research report on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $133.20.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $121.10 on Wednesday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The firm has a 50-day moving average of $123.27 and a 200-day moving average of $117.51. Gilead Sciences has a one year low of $88.57 and a one year high of $128.70. The company has a market cap of $150.25 billion, a P/E ratio of 18.78, a P/E/G ratio of 0.64 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the previous year, the company earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities research analysts forecast that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were given a dividend of $0.79 per share. The ex-dividend date was Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio is currently 48.99%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the transaction, the director owned 8,920 shares of the company’s stock, valued at $1,115,713.60. The trade was a 35.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Deborah H. Telman sold 53,646 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the completion of the sale, the executive vice president directly owned 43,676 shares in the company, valued at approximately $5,365,596.60. The trade was a 55.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 136,257 shares of company stock valued at $16,855,192. 0.27% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. GoalVest Advisory LLC grew its position in Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares in the last quarter. Corundum Trust Company INC bought a new stake in shares of Gilead Sciences during the 3rd quarter worth $26,000. Harbor Asset Planning Inc. bought a new position in Gilead Sciences in the second quarter valued at $27,000. Howard Hughes Medical Institute purchased a new stake in Gilead Sciences during the second quarter valued at about $30,000. Finally, Putney Financial Group LLC lifted its stake in Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.